Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Core Insights - Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment [3]. Company Overview - The company aims to harness the adaptive immune system's biology to transform disease diagnosis and treatment, believing it to be nature's most effective diagnostic and therapeutic tool [3]. - Adaptive Biotechnologies utilizes a proprietary immune medicine platform to decode the genetics of the adaptive immune system with scale, precision, and speed [3]. - The company partners with biopharmaceutical firms to inform drug development and develop clinical diagnostics in two main areas: Minimal Residual Disease (MRD) and Immune Medicine [3]. - Its commercial products and clinical pipeline target diseases such as cancer, autoimmune disorders, and infectious diseases, with a goal to create immune-driven clinical products tailored to individual patients [3]. Investor Engagement - The company will participate in the BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 12, 2025 [4]. - Additionally, it will engage in a fireside chat at the TD Cowen 45th Annual Health Care Conference on March 3, 2025, at 11:10 a.m. Eastern Time [4].